Literature DB >> 24614409

Targeted therapies: Is there a role for rituximab in nephrotic syndrome?

John Feehally1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24614409     DOI： 10.1038/nrneph.2014.37

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

1.  Rituximab's new therapeutic target: the podocyte actin cytoskeleton.

Authors:  Andrew C Chan
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

Review 2.  B-cell depletion in the treatment of lupus nephritis.

Authors:  Jon W Gregersen; David R W Jayne
Journal:  Nat Rev Nephrol       Date:  2012-07-17       Impact factor: 28.314

Review 3.  The pathogenesis of membranous nephropathy: evolution and revolution.

Authors:  Richard J Glassock
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-05       Impact factor: 2.894

4.  Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.

Authors:  Pietro Ravani; Alberto Magnasco; Alberto Edefonti; Luisa Murer; Rossella Rossi; Luciana Ghio; Elisa Benetti; Floriana Scozzola; Andrea Pasini; Nadia Dallera; Felice Sica; Mirco Belingheri; Francesco Scolari; Gian Marco Ghiggeri
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-12       Impact factor: 8.237

Review 5.  Rituximab in idiopathic nephrotic syndrome: does it make sense?

Authors:  Gabriel Cara-Fuentes; John A Kairalla; Takuji Ishimoto; Christopher Rivard; Richard J Johnson; Eduardo H Garin
Journal:  Pediatr Nephrol       Date:  2013-06-23       Impact factor: 3.714

6.  Efficacy of remission-induction regimens for ANCA-associated vasculitis.

Authors:  Ulrich Specks; Peter A Merkel; Philip Seo; Robert Spiera; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Barri J Fessler; Linna Ding; Lisa Viviano; Nadia K Tchao; Deborah J Phippard; Adam L Asare; Noha Lim; David Ikle; Brett Jepson; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Mark Mueller; Lourdes P Sejismundo; Kathleen Mieras; John H Stone
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

7.  Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.

Authors:  Piero Ruggenenti; Barbara Ruggiero; Paolo Cravedi; Marina Vivarelli; Laura Massella; Maddalena Marasà; Antonietta Chianca; Nadia Rubis; Bogdan Ene-Iordache; Michael Rudnicki; Rosa Maria Pollastro; Giovambattista Capasso; Antonio Pisani; Marco Pennesi; Francesco Emma; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2014-01-30       Impact factor: 10.121

Review 8.  Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases.

Authors:  Andrea G Kattah; Fernando C Fervenza; Dario Roccatello
Journal:  Autoimmun Rev       Date:  2012-09-19       Impact factor: 9.754

9.  Rituximab in children with resistant idiopathic nephrotic syndrome.

Authors:  Alberto Magnasco; Pietro Ravani; Alberto Edefonti; Luisa Murer; Luciana Ghio; Mirco Belingheri; Elisa Benetti; Corrado Murtas; Giovanni Messina; Laura Massella; Maria Gabriella Porcellini; Michela Montagna; Mario Regazzi; Francesco Scolari; Gian Marco Ghiggeri
Journal:  J Am Soc Nephrol       Date:  2012-05-10       Impact factor: 10.121

10.  Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).

Authors:  Hans-Peter Tony; Gerd Burmester; Hendrik Schulze-Koops; Mathias Grunke; Joerg Henes; Ina Kötter; Judith Haas; Leonore Unger; Svjetlana Lovric; Marion Haubitz; Rebecca Fischer-Betz; Gamal Chehab; Andrea Rubbert-Roth; Christof Specker; Jutta Weinerth; Julia Holle; Ulf Müller-Ladner; Ramona König; Christoph Fiehn; Philip Burgwinkel; Klemens Budde; Helmut Sörensen; Michael Meurer; Martin Aringer; Bernd Kieseier; Cornelia Erfurt-Berge; Michael Sticherling; Roland Veelken; Ulf Ziemann; Frank Strutz; Praxis von Wussow; Florian M P Meier; Nico Hunzelmann; Enno Schmidt; Raoul Bergner; Andreas Schwarting; Rüdiger Eming; Michael Hertl; Rudolf Stadler; Michael Schwarz-Eywill; Siegfried Wassenberg; Martin Fleck; Claudia Metzler; Uwe Zettl; Jens Westphal; Stefan Heitmann; Anna L Herzog; Heinz Wiendl; Waltraud Jakob; Elvira Schmidt; Klaus Freivogel; Thomas Dörner
Journal:  Arthritis Res Ther       Date:  2011-05-13       Impact factor: 5.156
  10 in total
  2 in total

Review 1.  Treatment of membranous nephropathy: time for a paradigm shift.

Authors:  Piero Ruggenenti; Fernando C Fervenza; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2017-07-03       Impact factor: 28.314

2.  B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome.

Authors:  Manuela Colucci; Rita Carsetti; Simona Cascioli; Federica Casiraghi; Annalisa Perna; Lucilla Ravà; Barbara Ruggiero; Francesco Emma; Marina Vivarelli
Journal:  J Am Soc Nephrol       Date:  2015-11-13       Impact factor: 10.121
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.